Reported about 1 month ago
Eli Lilly and Pfizer are embracing direct-to-consumer telehealth strategies to enhance medication sales and address competition. Lilly aims to protect its market for GLP-1 medications while Pfizer leverages its COVID-19 vaccine success to boost sales for other treatments. Both companies are investing in online platforms due to positive consumer experiences and data-driven insights, which may ultimately lead to improved patient engagement and adherence to medications, potentially disrupting traditional pharmaceutical distribution models.
Source: YAHOO